Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
January 30, 2017 12:22 PM EST
Wedbush lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $8.00 (from $13.00) while maintaining a Outperform rating after the FDA requested additional safety data from preclinical experiments and an ongoing trial extends the RG-101 / HCV clinical hold into Q1 2018
Liana Moussatos commented. "... we now anticipate the clinical... More
January 30, 2017 6:32 AM EST
Wells Fargo downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $2.25 yesterday.
...
More
January 30, 2017 5:58 AM EST
BMO Capital lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $2.00 (from $5.00) while maintaining a Market Perform rating after the FDA has extended RG-101's clinical hold.
Analyst Matthew Luchini commented, "Our probability of success declines to 25% from 40%, reflecting increased clinical... More
January 27, 2017 4:18 PM EST
Regulus Therapeutics (NASDAQ: RGLS) Shares to Resume Trading at 4:40 PM ET
...
More
January 27, 2017 4:11 PM EST
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug... More
January 27, 2017 4:06 PM EST
Regulus Therapeutics (NASDAQ: RGLS) Halted, News Pending
...
More
